GastroHep

Research Article

Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study

Table 1

Characteristics of patients with newly identified IAT stage^† HCC over the period 2015–2017 in the SNDS database.


Newly diagnosed IAT stage^† HCC population	Total
Newly diagnosed IAT stage^† HCC population	19,649 (100%)

Gender male (%)	16,210 (82.5%)
Age (years) at the identification of IAT stage^† HCC: mean (SD)	70.5 (11.0)
Duration of follow-up (month): mean (SD)	7.9 (7.3)
History of HCC curative treatment or type of disease progression
Previous curative treatment	3,205 (16.3%)
No curative treatment (de novo IAT stage^† at HCC diagnosis)	13,512 (68.8%)
Undetermined (lack of retrospective data in some patients with HCC diagnosed before 2013)	2,932 (14.9%)
HCC aetiology (several responses possible^‡)
Alcohol intake	10,328 (52.6%)
Viral hepatitis	3,635 (18.5%)
Metabolic risk factors^§	8,729 (44.4%)
Other liver diseases	11,218 (57.1%)
None identified liver disease in the database	2,596 (13.2%)

^†IAT stage: intermediate, advanced, or terminal stage; ^‡a single patient can have several HCC risk factors explaining the sum of percentages greater than 100; ^§Metabolic risk factors are NAFLD (nonalcoholic fatty liver disease), NASH (nonalcoholic steatohepatitis), or diabetes mellitus.